These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 22110164)
1. Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. Quaranta L; Katsanos A; Floriani I; Riva I; Russo A; Konstas AG J Clin Pharmacol; 2012 Oct; 52(10):1552-7. PubMed ID: 22110164 [TBL] [Abstract][Full Text] [Related]
2. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034 [TBL] [Abstract][Full Text] [Related]
3. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568 [TBL] [Abstract][Full Text] [Related]
4. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Schenker H; Maloney S; Liss C; Gormley G; Hartenbaum D Clin Ther; 1999 Jan; 21(1):138-47. PubMed ID: 10090431 [TBL] [Abstract][Full Text] [Related]
5. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study. Sonty S; Mundorf TK; Stewart JA; Stewart WC Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877 [TBL] [Abstract][Full Text] [Related]
6. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465 [TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Stewart WC; Konstas AG; Nelson LA; Kruft B Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886 [TBL] [Abstract][Full Text] [Related]
8. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost. Tamer C; Oksüz H Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours. Liu JHK; Slight JR; Vittitow JL; Scassellati Sforzolini B; Weinreb RN Am J Ophthalmol; 2016 Sep; 169():249-257. PubMed ID: 27457257 [TBL] [Abstract][Full Text] [Related]
11. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Liu JH; Medeiros FA; Slight JR; Weinreb RN Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559 [TBL] [Abstract][Full Text] [Related]
12. Effects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma. Quaranta L; Miglior S; Floriani I; Pizzolante T; Konstas AG Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4226-31. PubMed ID: 18502991 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure. Stewart WC; Leland TM; Cate EA; Stewart JA J Glaucoma; 1998 Dec; 7(6):402-7. PubMed ID: 9871862 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Shin DH; Feldman RM; Sheu WP; Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375 [TBL] [Abstract][Full Text] [Related]
15. Timolol maleate 0.5% versus timolol maleate in gel forming solution 0.5% (Timolol GFS) in open angle glaucoma in India. Preliminary safety and efficacy study. Kumar H; Sudan R; Sethi HS; Sony P Indian J Ophthalmol; 2002 Mar; 50(1):21-3. PubMed ID: 12090082 [TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081 [TBL] [Abstract][Full Text] [Related]
17. 24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. Konstas AG; Pikilidou MI; Tsironi S; Mikropoulos D; Kozobolis VP; Sarafidis PA; Lasaridis AN; Nelson LA; Stewart WC Curr Eye Res; 2009 May; 34(5):369-77. PubMed ID: 19401880 [TBL] [Abstract][Full Text] [Related]
18. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. Hatanaka M; Reis A; Sano ME; Susanna R J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119 [TBL] [Abstract][Full Text] [Related]
19. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WC Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391 [TBL] [Abstract][Full Text] [Related]
20. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Konstas AG; Tsironi S; Vakalis AN; Nasr MB; Stewart JA; Nelson LA; Stewart WC Acta Ophthalmol; 2009 Feb; 87(1):71-6. PubMed ID: 19178390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]